Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571

被引：3
|
作者：
Prejzner, W
Knopinska-Posluszny, W
Mikolajczuk, J
Langowska, B
Hellmann, A
机构：
[1] Med Acad Gdansk, Dept Haematol, PL-80211 Gdansk, Poland
[2] Med Acad Gdansk, Dept Clin Biochem, PL-80211 Gdansk, Poland
来源：
CLINICAL AND LABORATORY HAEMATOLOGY | 2003年 / 25卷 / 05期
关键词：
STI571; chronic myeloid leukemia; clonogenic capacity;
D O I：
10.1046/j.1365-2257.2003.00538.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
STI571 shows clinical activity in the treatment of chronic myelogenous leukemia, Philadelphia positive acute lymphoblastic leukemia and gastrointestinal stromal tumors. Resistance of normal progenitor cells to STI571 is essential when determining the optimal therapeutic window for patients with cancer without bone marrow involvement, and for patients with chronic myeloid leukemia who achieved complete cytogenetic remission. The effect of graded concentrations of STI571 on the clonogenic potential of normal fresh bone marrow hematopoetic progenitor cells from 13 normal individuals was analyzed. It was shown that lower concentrations of STI571 (0.1 and 0.5 mumol/l) may increase colony numbers, whereas higher concentrations (> 1 mumol/l) may reduce normal colony formation.
引用
收藏
页码：293 / 296
页数：4
相关论文
共 50 条
  • [1] The Role of the Tyrosine Kinase Inhibitor STI571 in the Treatment of Cancer
    O'Dwyer, Michael E.
    Druker, Brian J.
    CURRENT CANCER DRUG TARGETS, 2001, 1 (01) : 49 - 57
  • [2] Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis
    Beham-Schmid, C
    Apfelbeck, U
    Sill, H
    Tsybrovsky, O
    Höfler, G
    Haas, OA
    Linkesch, W
    BLOOD, 2002, 99 (01) : 381 - 383
  • [3] Effects of the tyrosine kinase inhibitor Imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia
    Thiele, J
    Kvasnicka, HM
    Schmitt-Graeff, A
    Kriener, S
    Engels, K
    Staib, P
    Griesshammer, M
    Waller, CF
    Ottmann, OG
    Hansmann, M
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (04) : 1277 - 1288
  • [4] The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells
    Podtcheko, A
    Ohtsuru, A
    Tsuda, S
    Namba, H
    Saenko, V
    Nakashima, M
    Mitsutake, N
    Kanda, S
    Kurebayashi, J
    Yamashita, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (04): : 1889 - 1896
  • [5] Regulation of cardiovascular remodeling by STI571, an inhibitor of PDGF receptor tyrosine kinase
    Takeda, N
    Iwata, H
    Niu, P
    Limuro, S
    Shindo, T
    CIRCULATION, 2004, 110 (17) : 115 - 115
  • [6] Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours
    Joensuu, H
    Dimitrijevic, S
    ANNALS OF MEDICINE, 2001, 33 (07) : 451 - 455
  • [7] Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571
    Yoshitani, K
    Honoki, K
    Morishita, T
    Kido, A
    Miyauchi, Y
    Mii, Y
    Takakura, Y
    IN VIVO, 2003, 17 (03): : 255 - 258
  • [8] Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571
    Bellone, G
    Ferrero, D
    Carbone, A
    De Quadros, MR
    Gramigni, C
    Prati, A
    Davidson, W
    Mioli, P
    Dughera, L
    Emanuelli, G
    Rodeck, U
    CANCER BIOLOGY & THERAPY, 2004, 3 (04) : 385 - 392
  • [9] The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells
    Ertmer, A
    Gilch, S
    Yun, SW
    Flechsig, E
    Klebl, B
    Stein-Gerlach, M
    Klein, MA
    Schätzl, HM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (40) : 41918 - 41927
  • [10] Effects of the tyrosine-kinase inhibitor STI571 on mutated KIT and neoplastic mast cells.
    Akin, C
    Longley, BJ
    Brockow, K
    Metcalfe, DD
    BLOOD, 2000, 96 (11) : 747A - 747A
12345